Kymera Therapeutics Inc

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is transitioning into a late-stage clinical organization following the completion of enrollment in its lead immunology program six months ahead of schedule. Management reported that cash reserves of $1.5 billion provide a runway into 2029, supporting the planned initiation of multiple Phase III studies across several indications. The company updated clinical timelines for its STAT6 and IRF5 degraders while reporting significant milestone revenue from established partnerships with Sanofi and Gilead Sciences. Leadership changes include the appointment of a new Chief Medical Officer and a new Chairman of the Board of Directors to guide the next phase of global clinical development and commercialization strategy.

Kymera Therapeutics reported a reduced second-quarter 2026 net loss of US$61.21 million and completed Phase 2b enrollment for its KT-621 atopic dermatitis trial roughly six months ahead of schedule. The company also maintained a cash balance of about US$1.50 billion and appointed Dr. Terence Rooney as Chief Medical Officer as it prepares for more than ten planned Phase III studies. These updates highlight Kymera's efforts to advance its immunology pipeline while managing sustained R&D spending without commercial products.

Kymera Therapeutics has appointed Terence Rooney, MD, as its new Chief Medical Officer. Dr. Rooney, formerly Senior Vice President and immunology portfolio leader at Johnson & Johnson, will oversee global clinical development strategy for the company's oral small molecule degrader pipeline targeting multiple immuno-inflammatory diseases. He succeeds Jared Gollob, MD, who is retiring after eight years with Kymera and will remain as an advisor through the end of 2026. Dr. Rooney brings experience from leadership roles at Johnson & Johnson, Eli Lilly, and Roche, and has contributed to marketing applications for medicines including ICOTYDE, IMAAVY, OLUMIANT, STELARA, and TREMFYA.

Kymera Therapeutics has completed enrollment in its phase IIb BROADEN2 study of oral STAT6 degrader KT-621 for moderate-to-severe atopic dermatitis about six months ahead of schedule, pulling forward pivotal efficacy data to the end of 2026. The company plans to begin phase III studies in atopic dermatitis by mid-2027 pending regulatory discussions, and KT-621 is also being investigated in the phase IIb BREADTH trial for moderate-to-severe eosinophilic asthma with data anticipated in late 2027. The candidate has received Fast Track designation from the FDA for both indications. Kymera had earlier reported positive phase Ib data demonstrating robust STAT6 degradation, reductions in type 2 inflammatory biomarkers, encouraging clinical activity, and a favorable safety profile, supporting its potential as an oral alternative to injectable biologics.

Kymera Therapeutics has appointed Elizabeth Laws as Senior Vice President and Global Program Team Leader for KT-621, its first-in-class oral STAT6 degrader. Dr. Laws, formerly an immunology leader at Sanofi, will oversee global development of the program, which is advancing through parallel Phase 2b trials in atopic dermatitis and asthma, with data expected by year-end 2026 and late 2027, respectively. Phase 3 trials in atopic dermatitis are planned to initiate by mid-2027. Kymera's CEO Nello Mainolfi highlighted her experience in bringing blockbuster therapies like dupilumab to patients at scale.

Kymera Therapeutics shares have risen 50.9% year to date, driven by rapid advancement of its lead candidate KT-621 for atopic dermatitis. The company completed enrollment in the phase IIb BROADEN2 study roughly six months ahead of schedule, pulling forward pivotal efficacy data to late 2026. Positive phase Ib data presented at the American Academy of Dermatology showed robust STAT6 degradation and a favorable safety profile, supporting KT-621 as a potential oral alternative to injectable biologics. Beyond KT-621, pipeline momentum includes dosing the first participant in a phase I trial of KT-485 under a Sanofi collaboration that triggered a $20 million milestone, new preclinical data for KT-579 in lupus models, and Gilead’s option exercise on KT-200 that brought a $45 million payment. Kymera plans to begin phase III studies in atopic dermatitis by mid-2027 and expects asthma data from the BREADTH trial in late 2027.

Kymera Therapeutics shares rose almost 30% this week after the company completed enrollment in a global Phase 2b trial of its lead drug candidate KT-621 far ahead of schedule, pulling the expected topline data readout forward to the end of this year from mid-2027. The drug is being tested for severe atopic dermatitis, a chronic skin condition. Several analysts raised their price targets following the news, with Canaccord's Edward Nash lifting his to $129 from $106 while maintaining a buy rating. The gains were partially offset by an insider sale in which Atlas Venture Fund, where board member and co-founder Bruce Booth is a partner, sold nearly 400,000 shares for roughly $44 million under a pre-arranged trading plan.

Kymera Therapeutics shares surged 16.6% on Thursday after the company completed enrollment in the global phase IIb BROADEN2 study of its lead candidate KT-621 for moderate to severe atopic dermatitis nearly six months ahead of schedule. The milestone prompted Kymera to accelerate its top-line data readout timeline to year-end 2026 from its earlier guidance of mid-2027. The phase IIb BROADEN2 study is a placebo-controlled, dose-ranging trial evaluating KT-621 in approximately 200 patients aged 12 to 75 years, with the primary endpoint measuring percent change from baseline in the Eczema Area and Severity Index score at week 16. KT-621 is an investigational once-daily oral degrader targeting STAT6, and it has already demonstrated deep STAT6 degradation and reductions in type II inflammatory biomarkers in a phase I study. Beyond atopic dermatitis, KT-621 is also being evaluated in the ongoing phase IIb BREADTH study for moderate-to-severe eosinophilic asthma, with top-line data expected in late 2027.

Several stocks made significant moves in midday trading. Kymera Therapeutics surged 17% after enrolling in a Phase 2b trial for its atopic dermatitis drug KT-621. BlackBerry rallied 20% on better-than-expected fiscal first-quarter results, posting adjusted earnings of 4 cents per share on revenue of $152.9 million. Apple slid nearly 5% after announcing price hikes on MacBooks and iPads, citing growing demand and rising memory and storage costs. AeroVironment fell 4% ahead of its fourth-quarter report next Monday and after disclosing it will restate prior results. Microsoft dropped 3.8% after saying it would raise Xbox console prices by $100 for the 512-gigabyte model and $150 for the 1-terabyte model. Hertz Global declined more than 9% following a 37-million share secondary offering priced at $2.70 per share. Micron soared 15% after third-quarter adjusted earnings of $25.11 per share blew past expectations, with revenue quadrupling to $41.46 billion. Qualcomm gained 8% after nearly doubling its 2029 non-handset revenue projection to $40 billion. Memory stocks also moved higher, with Sandisk jumping 18%, Western Digital rising 7%, and Lam Research adding 5%. Wendy's reversed earlier gains to trade down nearly 3% as retail trader momentum eased. Trip.com shed almost 2% after its fourth-quarter adjusted earnings and revenue missed expectations. Bio-Techne rallied 19.7% after agreeing to be acquired by Merck for $73 per share. Dollar Tree dropped 1.6% after a major shareholder sold shares in a block trade. McCormick gained 4% after reporting second-quarter adjusted earnings of 80 cents per share, topping estimates.